ADA and Wiskott-Aldrich syndrome: Therefore, SIN LVs have become more widely investigated for treating primary immune deficiencies (PIDs), such as, X-linked severe combined immunodeficiency (X-SCID), adenosine deaminase severe combined immunodeficiency (ADA-SCID) and Wiskott-Aldrich syndrome (WAS) (Fischer et al., 2015), as well as for treating metabolic disorders, such as, adrenoleukodystrophy and metachromatic leukodystrophy (Cartier et al., 2009; Biffi et al., 2013).